- Home
- SCLXW vs RWAYI Comparison
SCLXW vs RWAYI Comparison
Compare SCLXW & RWAYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCLXW | RWAYI |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCLXW | RWAYI |
|---|---|---|
| Price | $0.20 | $25.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.2K | 7.4K |
| Earning Date | 03-07-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,152,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.02 | N/A |
| 52 Week Low | $0.04 | $25.00 |
| 52 Week High | $0.64 | $25.93 |
Technical Indicators
Market Signals| Indicator | SCLXW | RWAYI |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 49.62 |
| Support Level | $0.09 | $25.10 |
| Resistance Level | $0.30 | $25.46 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 84.39 | 38.47 |
Price Performance
Historical ComparisonAbout SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.